Last reviewed · How we verify
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment (mild or moderate), or advanced age (65 years and more) in the routine clinical setting.
Details
| Lead sponsor | Takeda |
|---|---|
| Status | COMPLETED |
| Enrolment | 1026 |
| Start date | Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Oct 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 2 Diabetes Mellitus
Interventions
- Alogliptin and Metformin hydrochloride
Countries
Japan